Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Getting the annual RSV shot and other important vaccines is a fantastic way to safeguard yourself and your family as winter ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

Respiratory syncytial virus, or RSV, is a virus that causes infections of the lungs and breathing passages. It is highly ...

Oct. 30—(StatePoint) Each year, up to 160,000 older adults living in the United States are hospitalized and as many as 10,000 die due to respiratory syncytial virus (RSV). RSV is a highly ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Abrysvo is now approved for adults aged 18-59 years at increased risk for RSV due to chronic conditions, expanding its previous indications. The FDA's decision is based on a phase 3 trial showing ...

Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.

Oct. 30—(StatePoint) Each year, up to 160,000 older adults living in the United States are hospitalized and as many as 10,000 die due to respiratory syncytial virus (RSV). RSV is a highly contagious ...

“RSV represents a significant threat to younger adults with certain chronic conditions,” said Aamir Malik, Chief US Commercial Officer and Executive Vice President, Pfizer. “With this ...